Study Start-Up

Study Start-Up, or SSU, is the phase that prepares clinical trial sites for activation. It involves completing regulatory approvals, collecting essential documents, finalizing site readiness, and coordinating across multiple teams and systems—all while ensuring speed, accuracy, and compliance.

Traditionally, Study Start-Up is highly manual and fragmented. The following are some challenges encountered with these traditional methods:

• Manual Authoring of many complex documents, such as Study Protocol document, Form 1572, and many other regulatory submission documents, making it a highly manual, error-prone, and inefficient process, leading to risks of delays. Global clinical studies add complexity of local languages, requiring accurate translation of regulatory and operational documents to ensure clear, compliant communication.
• High regulatory burden and country-specific variability. Each country has its own regulations, formats, and compliance requirements, making global Study Start-Up difficult to standardize and even harder to scale.
• Manual follow-ups with the document owners to complete their documents on time. Potential delays go unnoticed until it is too late, leading to delayed submissions to health authorities.
• Reliance on emails, spreadsheets, and disconnected systems to track site visit plans, and IMP green light milestones. As a result, many SSU processes become person-dependent— relying heavily on individual expertise and tribal knowledge.